LEARNING OBJECTIVES

• Critically evaluate data from the pivotal clinical trials integrating novel molecular therapeutics into the treatment of various solid tumors, and communicate the scientific and patient-level advantages of selective cellular targeting.
• Describe the unique research and development challenges associated with identification of effective dosing, scheduling and duration of biologic and small-molecule antitumor agents.
• Evaluate the safety and tolerability of novel targeted compounds, and identify evidence-based strategies to manage side effects.
• Review the historical and evolving role of combination treatment strategies in the management of cancer, exploring the biologic rationale for concomitant versus sequential administration of cytotoxic and novel targeted compounds.
• Identify several distinct molecular pathways that support the development, growth, survival or invasive action of neoplastic cells, and describe the investigational agents that have demonstrated early anticancer activity through these mechanisms.
• Discuss the integral role of clinical trial participation in maximizing cancer treatment advances, and counsel appropriately selected patients on the relevance and availability of ongoing research studies.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity is a web-based video. To receive credit, the participant should review the Internet content and complete the Post-test and Educational Assessment and Credit Form located at www.BreastCancerUpdate.com/CME.

This program is supported by an educational grant from AstraZeneca Pharmaceuticals LP.